



Clinical and radiological findings of glioblastomas harboring a BRAF V600E mutation

Yukitomo Ishi¹ · Shigeru Yamaguchi¹ · Michinari Okamoto¹ · Ryosuke Sawaya¹ · Shogo Endo² · Hiroaki Motegi¹ · Shunsuke Terasaka³ · Zen-ichi Tanei⁴ · Kanako C. Hatanaka⁵ · Shinya Tanaka^{4,6} · Miki Fujimura¹

Received: 26 January 2022 / Accepted: 27 March 2022 / Published online: 1 April 2022
© The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology 2022

Abstract

The aim of this study was to analyze the clinical and radiological characteristics of glioblastomas (GBMs) harboring a *BRAF* mutation. Sequencing analysis of *BRAF*, *IDH1/2*, and *TERT* promoters was performed on GBM samples of patients older than 15 years. The clinical, pathological, and radiological data of patients were retrospectively reviewed. Patients were classified into three groups according to their *BRAF* and *IDH1/2* status: *BRAF* group, *IDH* group, and *BRAF/IDH*-wild-type (WT) group. Among 179 GBM cases, we identified nine cases with a *BRAF* mutation and nine with *IDH* mutation. The WT group had 161 cases. Age at onset in the *BRAF* group was significantly lower compared to the WT group and was similar to the *IDH* group. In cases with negative *IDH1*-R132H staining and age < 55 years, 15.2% were *BRAF*-mutant cases. Similar to the *IDH* group, overall survival of the *BRAF* group was significantly longer compared with the WT group. Among nine cases in the *BRAF* group, three cases had hemorrhagic onset and prior lesions were observed in two cases. In conclusion, age < 55 years, being *IDH1*-R132H negative, with hemorrhagic onset or the presence of prior lesions are factors that signal recommendation of *BRAF* analysis for adult GBM patients.

Keywords *BRAF* V600E · Glioblastoma · *IDH1/2* · MRI

Introduction

The World Health Organization (WHO) classification of central nervous tumors, revised in 2016, classified glioblastoma (GBM) into two groups according to the genetic status of *isocitrate dehydrogenase (IDH)*; that is, GBM-*IDH* mutant, and GBM-*IDH* wild-type (WT) [1]. In the 2021 WHO classification, *IDH*-mutant cases were classified as “astrocytoma, *IDH*-mutant grade 4,” and *IDH*-wild cases as “GBM, *IDH*-WT” [2]. Due to the poor prognosis of GBM despite standardized treatment with temozolomide (TMZ) and radiotherapy (RT), further molecular therapies targeting genetic alterations in GBMs have been explored [3].

A missense mutation at the amino acid position 600 of the *Braf proto-oncogene (BRAF V600E)* is frequently detected in pediatric low-grade gliomas, including 18–38.7% of gangliogliomas [4–6], 9–15.6% of pilocytic astrocytomas [4–6], and 50–66.7% of pleomorphic xanthoastrocytomas (PXAs) [4–7]. The *BRAF* mutation has been detected in a subset of GBMs [6, 8–11] and the majority of epithelioid GBMs (E-GBMs), which is an aggressive subtype of GBM [12, 13]. E-GBM has been described as a variant of GBM

✉ Shigeru Yamaguchi
yama-shu@med.hokudai.ac.jp

¹ Department of Neurosurgery, Hokkaido University School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

² Department of Neurosurgery, Hokkaido Neurosurgical Memorial Hospital, 1-20, Hachiken 9-jo, Higashi 5-chome, Nishi-ku, Sapporo 063-0869, Japan

³ Department of Neurosurgery, Kashiwaba Neurosurgical Hospital, 7-20, East 1-15 Tsukisamu, Toyohira-ku, Sapporo 062-8513, Japan

⁴ Department of Cancer Pathology, Hokkaido University School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

⁵ Department of Surgical Pathology, Hokkaido University Hospital, North 14 West 4, Kita-ku, Sapporo 060-8648, Japan

⁶ WPI-ICReDD, Hokkaido University, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

in the WHO classification in 2016 [1], and a histological pattern of “glioblastoma, IDH-wildtype” in the WHO classification in 2021 [14]. Regarding the molecular features of GBM with the *BRAF* mutation (*BRAF*-GBM), recent studies have revealed that a missense mutation in the promoter of *telomerase reverse transcriptase* (*TERT*) and homozygous deletion of *cyclin-dependent kinase inhibitor 2A* (*CDKN2A-HD*) were frequent and similar to *IDH*-wild GBMs [13, 15]. However, the clinical features of *BRAF*-GBM have not been elucidated due to the low number of cases.

The efficacy of targeting therapy for *BRAF* V600E using dabrafenib and trametinib have been reported in clinical experiences [16–25]. To screen the potential targeting therapy candidates for *BRAF* V600E, clinical sequencing of cancer-associated genes would be the most appropriate approach in clinical practice [26]. However, there are no standardized principles to recommend clinical sequencing in GBM patients, and the clinical characteristics of *BRAF*-GBM would have significant value for recommendation of *BRAF* screening. The aim of this study was to reveal the clinical and radiological features of *BRAF*-GBM.

Methods

Patient population

This study included patients with GBM who underwent treatment in Hokkaido University Hospital from 2000 to 2021 and whose frozen tumor tissues were available. Adult and young adult patients older than 15 years of age were included. Pathological diagnoses of GBM were provided by institutional pathologists according to the WHO classification of Central Nervous System revised 4th edition in 2016 [27]. Clinical, pathological, and radiological data of patients were retrospectively analyzed by referring to their medical record. All manipulations were performed under approval from our institutional review board. As this study was retrospective, the requirement for informed consent was waived.

Genetic analysis

DNA/RNA was extracted from frozen tumor tissues using an AllPrep DNA/RNA Mini Kit (Qiagen, Tokyo, Japan) in accordance with the manufacturer’s recommendations. Two hotspots within the *TERT* promoter (C228T, C250T), along with mutation hotspots at codon 132 of *IDH1*, codon 172 of *IDH2*, and codon 600 of *BRAF* were screened using Sanger sequencing, as previously described [28]. *CDKN2A-HD* was analyzed by multiplex ligation-dependent probe amplification [8], or we referred to the result of the clinical sequencing panel using FoundationOne CDx (Foundation Medicine, Cambridge, USA) or OncoGuide™ (Sysmex, Kobe, Japan).

Statistical analysis

Statistical analysis was performed using Graphpad Prism 8 (GraphPad Software, San Diego, CA). A *p* value less than 0.05 was considered statistically significant for a log-rank test and analysis of variance (ANOVA) with a Tukey–Kramer test as a post hoc analysis.

Results

Patient demographics

Among the 179 cases analyzed in this study, mutations in *BRAF*, *IDH1/2*, and *TERT* promoter mutations were detected in 9 cases (5.0%), 9 cases (5.0%) and 96 cases (54.9%), respectively (Fig. 1a). None of the *BRAF*-mutant cases presented co-occurrence with the *IDH* mutation and one case with the *BRAF* mutation presented co-occurrence with the *TERT* promoter mutation. Pathological diagnoses in *BRAF*-mutant cases were classical GBM in eight cases and epithelioid GBM in one case. Eight of nine cases had a *BRAF* V600E mutation and one case had an in-frameshift deletion with *BRAF* c.1799_1801del that resulted in p.V600E and p.K601del. *CDKN2A-HD* was detected in seven cases (Table 1). In this study, we classified the cases into three groups according to the status of *BRAF* and *IDH1/2*: *BRAF*-mutant (*BRAF* group, 9 cases), *IDH1/2*-mutant (*IDH* group, 9 cases), and wild-type *BRAF* and *IDH1/2* (WT group, 161 cases).

Clinical characteristics of GBM with the *BRAF* mutation

Clinical features of nine cases with the *BRAF* mutation, including eight cases with classical GBM and one case with E-GBM, are summarized in Table 1. The median age at onset of the *BRAF* group was 37 years (range 27–66), which was significantly younger than the WT group but was similar to the *IDH* group (Fig. 1b). Among 46 cases with negative *IDH1*-R132H staining and age < 55 years, seven cases with a *BRAF*-mutant accounted for 15.2%, while no cases presented with the *IDH1/2* mutation (Fig. 1c). Major symptoms at onset were seizure in three patients and stroke-like symptoms due to intratumoral hemorrhage in three patients. All patients except for one case had a single lesion that arose in a cerebral hemisphere.




Fig. 1 Patient demographics and clinical features of a GBM with a *BRAF* mutation in this study. **a** Genetic landscape presenting mutations of *BRAF*, *IDH1/2*, and *TERT* promoters in nine cases (5.0%), nine cases (5.0%), and 96 cases (54.9%), respectively. **b** Age at onset [median (range)] in the *BRAF* group, *IDH* group, and *WT* group was 37 (27–66) years, 43 (22–67) and 63 (15–89) years, respectively. Age at onset in the *BRAF* group and *IDH* group was significantly younger than in the *WT* group ($p=0.0005$ and $p=0.0151$, respectively).

Treatment outcome of GBM with a *BRAF* mutation

Five out of nine cases with *BRAF*-GBM showed recurrence including dissemination in four cases during observation period (Table 1). The survival curve of the *BRAF* group within 24 months was similar to the *WT* group due to early death; however, the presence of patients with long-term survival resulted in significantly longer overall survival (OS) compared with the *WT* group (Fig. 1d). There was no significant difference between the *BRAF* group and *IDH* group, which also presented a favorable OS compared with the *WT* group (Fig. 1d).

Radiological findings of GBM with *BRAF* mutation

Among 6 cases without hemorrhagic onset, all cases showed enhanced lesions on gadolinium-enhanced (Gd-) T1 weighted imaging (WI), while 3 cases (cases 1, 4, and 6) had mild perifocal edema on T2WI or fluid attenuated inversion recovery (FLAIR) on MRI (Supplementary Figure). A well-circumscribed border on Gd-T1WI was observed in five cases (cases 1–4 and 6, cortical involvement was observed in three cases (cases 1, 2, and 6), and a large cystic component was observed in one case (case 2). Among three cases with hemorrhagic onset, two cases

had a prior lesion on FLAIR that was diagnosed at 3 and 8 years before, respectively (Table 1).

ANOVA: *, $p < 0.05$, ***, $p < 0.001$. **c** Among 46 cases with negative *IDH1*-R132H staining and age < 55 years, a *BRAF* mutation was detected in seven cases (15.2%) and no cases harbored an *IDH1/2* mutation. **d** Kaplan–Meier survival curve in this study presenting significantly longer OS for the *BRAF* group and *IDH* group compared with the *WT* group ($p=0.0364$ and $p=0.0162$, respectively). CI = confidence interval; HR = hazard ratio

Representative cases

Case #1 (non-hemorrhagic onset, long-term survival without recurrence)

A 27-year-old female presented with convulsive and repeated dysosmia, which was considered as partial seizures. MRI showed a mass lesion in the mesial temporal lobe, in which Gd-T1WI showed ring-like enhancement with a well-circumscribed border and cortical involvement and FLAIR showed mild perifocal edema (Fig. 2a, Supplementary Figure). Gross total removal (GTR) was achieved at tumor resection. A pathological examination indicated a necrotic area (Fig. 2b) and dense tumor cells with nuclear atypia and mitosis (Fig. 2c). The Ki-67 labeling index was 50% and the pathological diagnosis was GBM. The patient underwent oral administration of TMZ (75 mg/m²), 60 Gy (Gy) of local RT, and a subsequent maintained administration of TMZ (150 mg/m²/4 weeks). She had no neurological deficit and no recurrence for 69 months.

Table 1 Summary of BRAF-GBM in this study

Case	Age at onset (years)	Gender	Initial symptom	Location	Prior lesion	Pathological diagnosis	BRAF	IDH1/2	TERT	CDKN2A	Recurrence	OS (months)	Status
1	27	F	Seizure	Temporal lobe	Unknown	GBM	V600E	WT	WT	HD	-	77	A
2	37	M	Seizure	Parietal lobe	Unknown	GBM	V600E	WT	WT	HD	-	38	A
3	37	M	Verbal abnormality	Temporal lobe	Unknown	GBM	V600E	WT	WT	HD	+ Dis	84	D
4	42	M	Seizure	Frontal lobe	Unknown	E-GBM	V600E	WT	WT	HD	+ Dis	5	D
5	61	M	Facial numbness	Multifocal	Unknown	GBM	V600E	WT	WT	HD	+	12	D
6	66	M	Consciousness disturbance	Temporal lobe	Unknown	GBM	V600E, K601del	WT	WT	No loss	+ Dis	37	D
7	44	F	Stroke-like (hemorrhagic)	Frontal lobe	Unknown	GBM	V600E	WT	WT	No loss	-	48	A
8	31	M	Stroke-like (hemorrhagic)	Occipital lobe	+(28-year-old)	GBM	V600E	WT	WT	HD	+ Dis	29	D
9	38	M	Stroke-like (hemorrhagic)	Temporal lobe	+(30-year-old)	GBM	V600E	WT	C250T	HD	-	30	A

A, alive; D, dead; Dis, dissemination; E-GBM, epithelioid glioblastoma; F, female; GBM, glioblastoma; HD, homozygous deletion; M, male; OS, overall survival; WT, wild-type

Case #4 (non-hemorrhagic onset, early recurrence)

A 42-year-old male presented with a grand mal seizure. MRI indicated a tumor in the right frontal lobe with ring-like enhancement and a well-circumscribed border on Gd-T1WI and mild perifocal edema on FLAIR (Fig. 2d, Supplementary Figure). GTR was achieved at tumor resection. A pathological examination identified dense tumor cells with nuclear atypia, microvascular proliferation, and necrosis (Fig. 2e). Gemistocytic tumor cells were also observed (Fig. 2f) and the pathological diagnosis was E-GBM. He underwent oral administration of TMZ (75 mg/m²), 60 Gy of RT, and a subsequent maintained administration of TMZ. However, local recurrence and spinal dissemination were detected at 3 months after surgery and he died five months after surgery.

Case #7 (hemorrhagic onset)

A 44-year-old female presented with sudden onset of headache and aphasia. Head CT showed a high-density lesion on the left insula and FLAIR on MRI showed a high-intensity lesion surrounding the hematoma, which suggested hemorrhagic onset of an intra-axial tumor (Fig. 3a). Emergent surgery was performed, and the pathological specimens exhibited hematoma with a small amount of diffuse astrocytoma showing the Ki-67 labeling index of 5% (Fig. 3b). Based on the postoperative MRI presenting no apparent residual lesion (Fig. 3c) and low-grade histological malignancy, the patient was carefully observed without additional treatment; however, MRI showed recurrence at nine months after surgery (Fig. 3d). She underwent additional surgery and subtotal removal was achieved. Pathological examinations presented increased tumor cell density and nuclear atypia. The Ki-67 labeling index was 25% and the diagnosis was GBM (Fig. 3e). She underwent oral administration of TMZ (75 mg/kg) and 60 Gy of irradiation followed by 24 courses of maintained administration of TMZ. She had no apparent recurrence for 39 months after treatment.

Case #8 (hemorrhagic onset with a prior lesion)

This male patient was shown to have an intra-axial lesion on the right occipital lobe due to headache at the age of 28 years (Fig. 4a), and he was observed at another institution. At the age of 31 years, he presented with a sudden onset headache. Head CT showed a high-density lesion in the right occipital lobe, and MRI showed mild perifocal edema and heterogenous enhancement in the lesion (Fig. 4b). Emergent surgery was performed and GTR was achieved. The pathological diagnosis was GBM (Fig. 4c) and he underwent oral administration of TMZ and 60 Gy of RT followed by maintenance TMZ. However, he underwent additional resection surgery for local recurrence at 10 months after the




Fig. 2 Radiological and pathological findings of representative cases with non-hemorrhagic onset (**a–c**: case 1, **d–f**: case 4). **a** Preoperative Gd-T1WI of MRI of case 1 who had a tumor with ring-like enhancement in the left mesial temporal lobe. **b** HE staining of case 1 (original magnification 4 \times , scale bar=200 μ m) showing global necrosis. **c** HE staining of case 1 (original magnification 20 \times , scale bar=50 μ m) showing dense tumor cells with nuclear atypia. **d** Preoperative Gd-

T1WI of MRI of case 4 who had a tumor with ring-like enhancement in the right frontal lobe. **e** HE staining of case 4 (original magnification 4 \times , scale bar=200 μ m) showing global necrosis and microvascular proliferation. **f** HE staining of case 4 (original magnification 40 \times , scale bar=20 μ m) showing dense tumor cells with nuclear atypia with gemistocytic tumor cells supporting the diagnosis of E-GBM

initial surgery. Although he was treated with TMZ and bevacizumab, distant recurrence was observed 7 months later. Clinical sequencing revealed *BRAF* V600E and he started combined treatment with dabrafenib and trametinib, but he died due to progression of the disease at 29 months after initial treatment.

Case #9 (hemorrhagic onset with a prior lesion)

This male patient was diagnosed in other institution with a right temporal lobe abnormality on MRI at the age of 30 years due to epilepsy (Fig. 4d); however, surgical confirmation was not performed, because the patient did not consent. At the age of 38 years, he presented with sudden onset of headache. Head CT showed a high-density lesion in the right temporal lobe, FLAIR on MRI showed a high-intensity lesion around the hemorrhage, and Gd-T1WI showed ring-like enhancement (Fig. 4e). Emergent surgery was performed and the pathological diagnosis was GBM (Fig. 4f). He underwent standardized treatment with TMZ and 60 Gy of irradiation, and salvage surgery for the remaining lesion was performed after irradiation. He continued TMZ

maintenance without evidence of recurrence for 30 months after the initial surgery.

Discussion

Previous reports indicated that the *BRAF* mutation accounted for 1.6–6.3% of adult GBM cases [6, 8–10] and 15 of 633 (2.4%) adult high-grade gliomas including WHO grade 3 cases [8]. The *BRAF* mutation has been observed more frequently with 16 of 107 (15.0%) cases in the study of young adult GBM cases [11]. Our results also indicated younger ages at onset in *BRAF*-mutated cases as well as *IDH*-mutant cases, which was consistent with previous reports [29, 30]. Because of the low frequency of *IDH* mutations in the elderly, the current WHO classification recommends sequencing analysis of *IDH1/2* in cases with age < 55 years if immunostaining for IDH1-R132H is negative [1]. Although cases with co-occurrence of *BRAF* and *IDH1/2* mutations have been reported [5, 12, 29], most of the *BRAF*-mutated cases did not harbor the *IDH1/2* mutation [8, 10, 11]. Thus, we consider that analysis of the *BRAF*




Fig. 3 Radiological and pathological findings of a representative case with hemorrhagic onset (Case 7). **a** Radiological findings at presentation (left: CT, right: FLAIR) indicating a high-density lesion in the left insular cortex and high intensity lesion surrounding the hemorrhage. **b** HE staining (original magnification 20 \times , scale bar = 50 μ m) showing diffusely proliferating astrocytic tumor cells with a prominent eosinophilic cytoplasm and multinucleated giant cells and occa-

sional microcalcification. **c** Postoperative FLAIR of MRI indicating removal of the right putaminal hemorrhage. **d** Gd-T1WI of MRI taken at nine months after the initial surgery indicating the recurrence of a ring-like enhanced lesion. **e** HE staining (original magnification 20 \times , scale bar = 50 μ m) showing dense pleomorphic tumor cells with nuclear atypia

mutation would be valuable, especially in patients who are less than 55 years old and are negative for *IDH1*-R132H as presented in our study.

Dissemination, which is frequent in E-GBM cases [13, 15], was observed in four out of five recurrent cases including one E-GBM case in this study. Classical GBM with *BRAF* mutation, as well as E-GBM cases, would tend to present dissemination at recurrence. Although *BRAF*-GBM tended to present favorable treatment outcomes compared to other *IDH*-wild GBMs in this study, the *BRAF* mutation has also been detected in E-GBMs that are associated with aggressive clinical behaviors [13, 15]. Indeed, early death after initial treatment was observed in a subset of cases in this study (Case 4), and another cohort including a higher percentage of E-GBMs indicated no survival benefit with a *BRAF* mutation compared with *BRAF*-WT cases [31]. Thus, further molecular biomarkers associated with prognoses should be clarified in *BRAF*-GBMs. Previous reports have revealed frequent combinations of *TERT* promoter mutation both in epithelioid GBMs and classical GBMs with a *BRAF* mutation [13, 15, 16, 29]. In our series, a combination of *BRAF* mutation and *TERT* promoter mutation

was detected only in one patient with a classical GBM. Although the *TERT* promoter mutation has been reported as a poor prognosis marker of *IDH*-wild GBMs [32], it is still unclear whether the *TERT* promoter mutation is a prognostic marker in *BRAF*-mutant GBMs. *CDKN2A*-HD has also been detected in a large fraction of *BRAF*-mutant GBMs, which suggests the important role of tumorigenesis in *BRAF*-GBM. However, the diagnostic value of *CDKN2A*-HD in *BRAF*-GBMs is still unclear.

A well-circumscribed border and mild perifocal edema on MRI were frequent in non-hemorrhagic cases in this study and similar findings have been reported in previous studies [9, 29, 33]. However, a recent study suggested that a combination of well-circumscribed borders, large cysts, and cortical involvement was more definitive in *BRAF*-mutant cases rather than the extent of perifocal edemas [31]. Although one patient in our study had multifocal lesions and cases with diagnosis of gliomatosis cerebri harboring a *BRAF* mutation have been reported [6, 29, 34], the majority of *BRAF*-GBMs show a single lesion on MRI [9, 20, 22, 25, 29, 31].

In our series, a prior lesion and hemorrhagic onset were observed in two and three cases, respectively, both




Fig. 4 Radiological and pathological findings of representative cases with a prior lesion and hemorrhagic onset (**a–c**: case 8, **d–f**: case 9). **a** FLAIR of case 8 taken at the age of 28 years showing a high intensity lesion in the right occipital lobe. **b** Radiological findings of case 8 at 31 years of age (left: CT, middle FLAIR, right: Gd-T1WI) showing a high-density lesion with hemorrhage surrounding a high intensity lesion and heterogeneous enhancement in the wall of the lesion in the right occipital lobe. **c** HE staining of case 8 (original magnification

10 \times , scale bar=100 μ m) showing highly cellular tumor cells with palisading necrosis. **d** FLAIR of case 9 taken at the age of 30 years showing a high intensity lesion in the right temporal lobe. **e** Radiological findings of case 9 at 31 years of age (left: CT, right: FLAIR) showing a high-density lesion with hemorrhage and a surrounding high intensity lesion in the right temporal lobe. **f** HE staining (original magnification 40 \times , scale bar=20 μ m) indicating astrocytic tumor cells with a monomorphic population

of which have not been reported as characteristics of *BRAF*-GBM previously. Prior lesions would suggest the presence of low-grade pathology, which supports the hypothesis that a subset of *BRAF*-GBMs arise from low-grade *BRAF*-associated tumors, such as PXA [35, 36]. Hemorrhagic onset is a rare clinical presentation in GBMs and several underlying mechanisms such as perivascular necrosis with subsequent loss of vessel support, thin walled or poorly formed vessels, endothelial proliferation with subsequent obliteration of the lumen, and the presence of intratumoral arteriovenous fistulae have been reported [37]. Among previous cases with *BRAF*-GBM, one patient with hemorrhagic onset has been reported [38]. Although the specific mechanism of hemorrhage associated with the *BRAF* mutation is unclear in pathological and radiological examinations in our cases, considering the frequency in this study, hemorrhagic onset may be frequent in *BRAF*-GBM cases.

Conclusions

Analysis of *BRAF* in GBM cases is recommended, especially in patients younger than 55 years of age and *IDH1*-R132 negative cases. Considering the clinical course, a prior lesion and hemorrhagic onset suggest the possible presence of a *BRAF* mutation.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10014-022-00432-7>.

Acknowledgements The authors would like to thank Enago (www.enago.jp) for the English language review.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

References

- Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* 131:803–820
- Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. *Neuro Oncol*. <https://doi.org/10.1093/neuonc/noab106>
- Taslimi S, Ye VC, Zadeh G (2021) Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. *Neurooncol Adv* 3:vdab08
- Chappe C, Padovani L, Scavarda D et al (2013) Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. *Brain Pathol* 23:574–583
- Myung JK, Cho H, Park CK et al (2012) Analysis of the BRAF(V600E) mutation in central nervous system tumors. *Transl Oncol* 5:430–436
- Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. *Acta Neuropathol* 121:397–405
- Lee D, Cho YH, Kang SY et al (2015) BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. *J Surg Oncol* 111:359–364
- Arita H, Yamasaki K, Matsushita Y et al (2016) A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. *Acta Neuropathol Commun* 4:79
- Hatae R, Hata N, Suzuki SO et al (2017) A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. *Neuropathology* 37:191–199
- Park CK, Lee SH, Kim JY et al (2014) Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma. *Oncotarget* 5:3399–3407
- Zhang RQ, Shi Z, Chen H et al (2016) Biomarker-based prognostic stratification of young adult glioblastoma. *Oncotarget* 7:5030–5041
- Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. *Am J Surg Pathol* 37:685–698
- Sun K, Zhou X, Li T et al (2021) Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. *Neurosurg Rev*. <https://doi.org/10.1007/s10143-021-01492-7>
- Louis DN, Giannini C, Perry A et al (2021) Glioblastoma, IDH-wildtype. In: WHO Classification of Central nervous system tumours [Internet], 5th edn. International Agency for Research on Cancer, Lyon (France). <https://tumourclassification.iarc.who.int/chapters/45>
- Nakajima N, Nobusawa S, Nakata S et al (2017) BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity. *Brain Pathol*. <https://doi.org/10.1111/bpa.12572>
- Dono A, Vu J, Anapolsky M et al (2020) Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. *J Neurooncol* 149:463–472
- Johanns TM, Ferguson CJ, Grierson PM et al (2018) Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. *J Natl Compr Canc Netw* 16:4–10
- Kaley T, Touat M, Subbiah V et al (2018) BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. *J Clin Oncol* 36:3477–3484
- Kanamaru Y, Natsumeda M, Okada M et al (2019) Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. *Acta Neuropathol Commun* 7:119
- Kushnirsky M, Feun LG, Gultekin SH et al (2020) Prolonged Complete response with combined dabrafenib and trametinib after BRAF Inhibitor failure in BRAF-mutant glioblastoma. *JCO Precis Oncol* 2020:4
- Lin Z, Xu H, Yang R et al (2021) Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report. *Anticancer Drugs*. <https://doi.org/10.1097/cad.0000000000001130>
- Qin C, Long W, Zhang C et al (2020) Multidisciplinary therapy managed recurrent glioblastoma in a BRAF-V600E mutant pregnant female: a case report and review of the literature. *Front Oncol* 10:522816
- Robinson GW, Orr BA, Gajjar A (2014) Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy. *BMC Cancer* 14:258
- Venkatesh A, Joshi A, Allinson K et al (2021) Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: a case report and literature review. *Curr Probl Cancer*. <https://doi.org/10.1016/j.currprobcancer.2020.100701:100701>
- Woo PYM, Lam TC, Pu JKS et al (2019) Regression of BRAF (V600E) mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. *Oncotarget* 10:3818–3826
- Ebi H, Bando H (2019) Precision oncology and the universal health coverage system in Japan. *JCO Precis Oncol* 2019:3
- Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification of tumours of the central nervous system. Revised 4th edition. In: International Agency for Research on Cancer, Lyon
- Ishi Y, Takamiya S, Seki T et al (2020) Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas. *Brain Tumor Pathol*. <https://doi.org/10.1007/s10014-020-00369-9>
- Lim-Fat MJ, Song KW, Iorgulescu JB et al (2021) Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. *J Neurooncol* 152:515–522
- McNulty SN, Schwetye KE, Ferguson C et al (2021) BRAF mutations may identify a clinically distinct subset of glioblastoma. *Sci Rep* 11:19999
- Natsumeda M, Chang M, Gabdulkaev R et al (2021) Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. *Brain Tumor Pathol*. <https://doi.org/10.1007/s10014-021-00407-0>
- Nonoguchi N, Ohta T, Oh JE et al (2013) TERT promoter mutations in primary and secondary glioblastomas. *Acta Neuropathol* 126:931–937
- Suzuki Y, Takahashi-Fujigasaki J, Akasaki Y et al (2015) BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. *Brain Tumor Pathol*. <https://doi.org/10.1007/s10014-015-0234-4>
- Fernandez-Vega I, Quirk J, Norwood FL et al (2014) Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation. *Pathol Oncol Res* 20:215–220
- Tanaka S, Nakada M, Nobusawa S et al (2014) Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation. *Brain Tumor Pathol* 31:172–176

36. Watanabe N, Ishikawa E, Kohzuki H et al (2020) Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report. *BMC Neurol* 20:21
37. Joseph DM, O'Neill AH, Chandra RV et al (2017) Glioblastoma presenting as spontaneous intracranial haemorrhage: case report and review of the literature. *J Clin Neurosci* 40:1–5
38. Chi AS, Batchelor TT, Yang D et al (2013) BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. *J Clin Oncol* 31:e233-236

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.